BioWorld

Jan. 11, 2002

View Archived Issues

Corixa’s Bexxar ODAC Hearing Delayed While FDA Sorts Data

Despite reassurances from Corixa Corp. that there s nothing wrong with its lead drug candidate, Bexxar, the Seattle company s stock tumbled Thursday on news that the FDA has delayed an application hearing for the product. Read More

Access Oncology To Pay Up To $33M For Doxorubicin Analogues

Read More

Old Order Changeth; Genomics Yields Place To New Proteomics For Deciphering Gene Functions

Read More

GenVec To Collaborate With NIH On AIDS Vaccine Development

Read More

Other News To Note

Read More